With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
The results signal shift beyond paclitaxel-coated balloon (PCB) angioplasty in femoropopliteal artery disease
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
The agreements aim to strengthen medicine quality, patient safety and pharmaceutical research in India
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
Extending production capabilities to the Americas helps reduce labor costs and inventory complexity for nutraceuticals and other industries while maintaining superior moisture control
Aims to boost speed & precision in patient care
Three-day programme focuses on advanced socket design, myoelectric technology and clinical skill development
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
SBE303 targets Nectin-4, an adhesion protein overexpressed in multiple tumor types, including urothelial, lung, and breast cancers
Subscribe To Our Newsletter & Stay Updated
